Natural Investments LLC Invests $194,000 in Takeda Pharmaceutical Co. $TAK

Natural Investments LLC purchased a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) in the second quarter, HoldingsChannel reports. The institutional investor purchased 12,563 shares of the company’s stock, valued at approximately $194,000.

Other large investors also recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $37,000. Farther Finance Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after buying an additional 1,045 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Takeda Pharmaceutical by 85.5% during the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock worth $78,000 after buying an additional 2,411 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Takeda Pharmaceutical in the first quarter valued at $125,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Saturday, September 27th. Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Takeda Pharmaceutical has an average rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $13.73 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The stock has a fifty day moving average price of $14.86 and a two-hundred day moving average price of $14.79. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.69. The firm has a market capitalization of $43.69 billion, a P/E ratio of 45.77 and a beta of 0.21.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.